Breast cancer risk associated with genotypic polymorphism of the genes involved in the estrogen-receptor-signaling pathway: A multigenic study on cancer susceptibility

Journal of Biomedical Science

Volumn 13, Issue 3, 2006, Pages 419-432

  Yu, Jyh Cherng ^a   Hsu, Huan Ming ^a,b   Chen, Shou Tung ^c   Hsu, Giu Cheng ^a   Huang, Chiun Sheng ^d   Hou, Ming Feng ^e   Fu, Yi Ping ^b   Cheng, Ting Chih ^b   Wu, Pei Ei ^b   Shen, Chen Yang ^b,f  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f ACADEMIA SINICA   (Taiwan)

Author keywords

Breast cancer; E cadherin; Estrogen; Estrogen receptor; Genetic polymorphism; MTA1; MTA3; Snail

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GENE PRODUCT; METASTASIS ASSOCIATED 1 PROTEIN; ONCOPROTEIN; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CELL GROWTH; CELL NUCLEUS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DNA POLYMORPHISM; EPIDEMIOLOGICAL DATA; ESTROGEN ACTIVITY; FEMALE; GENE EXPRESSION; GENE TARGETING; GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYPOTHESIS; MAJOR CLINICAL STUDY; METASTASIS ASSOCIATED 3 GENE; OBESITY; ONCOGENE; PREGNANCY; PRIORITY JOURNAL; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; TUMOR PROMOTION;

BREAST NEOPLASMS; CADHERINS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HISTONE DEACETYLASES; HUMANS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; POLYMORPHISM, GENETIC; RECEPTORS, ESTROGEN; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION;

GASTROPODA;

EID: 33646586374     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1007/s11373-006-9069-7     Document Type: Article

References (45)

1. Hulka B.S. and Stark A.T., Breast cancer: cause and prevention. Lancet 346: 883-887, 1995.
2. Kelsey J.L., Gammon M.D. and John E.M., Reproductive factors and breast cancer. Epidemiol. Rev. 15: 36-47, 1993.
3. Pike M.C., Spicer D.V., Dahmoush L. and Press M.F., Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev. 15: 17-35, 1993.
4. Gruber C.J., Tschugguel W., Schneeberger C. and Huber J.C., Production and actions of estrogens. N. Engl. J. Med. 346: 340-352, 2002.
5. Dickson R.B. and Stancel G.M., Estrogen receptor-mediated processes in normal and cancer cells. J. Natl. Cancer Inst. Monogr. 27: 135-145, 2000.
6. Frasor J., Danes J.M., Komm B., Chang K.C., Lyttle C.R. and Katzenellenbogen B.S., Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144: 4562-4574, 2003.
7. Fujita N., Kajita M., Taysavang P. and Wade P.A., Hormonal regulation of metastasis-associated protein 3 transcription in breast cancer cells. Mol. Endocrinol. 18: 2937-2949, 2004.
8. Fujita N., Jaye D.L., Kajita M., Geigerman C., Moreno C.S. and Wade P.A., MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 113: 207-219, 2003.
9. Kumar R., Wang R.A. and Bagheri-Yarmand R., Emerging roles of MTA family members in human cancers. Semin. Oncol. 30((5 Suppl 16)) 30-37, 2003.
10. Batlle E., Sancho E., Franci C., Dominguez D., Monfar M., Baulida J. and Garcia De Herreros A., The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2: 84-89, 2000.
11. Fearon E.R., Connecting estrogen receptor function, transcriptional repression, and E-cadherin expression in breast cancer. Cancer Cell 3: 307-310, 2003.
12. Kumar R., Another tie that binds the MTA family to breast cancer. Cell 113: 142-143, 2003.
13. Ding S.L., Sheu L.F., Yu J.C., Yang Y.L., Chen B., Leu F.J. and Shen C.Y., Expression of estrogen receptor-alpha and Ki67 in relation to pathological and molecular features in early-onset infiltrating ductal carcinoma. J. Biomed. Sci. 11: 911-919, 2004.
14. Gold B., Kalush F., Bergeron J., Scott K., Mitra N., Wilson K., Ellis N., Huang H., Chen M., Lippert R., Halldorsson B.V., Woodworth B., White T., Clark A.G., Pari F.F., Broder S., Dean M. and Offit K., Estrogen receptor genotypes and haplotypes associated with breast cancer risk. Cancer Res. 64: 8891-8900, 2004.
15. Shen C.Y., Yu J.C., Lo Y.L., Kuo C.H., Yue C.T., Jou Y.S., Huang C.S., Lung J.C. and Wu C.W., Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma- an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res. 60: 3884-3892, 2000.
16. Cheng C.W., Wu P.E., Yu J.C., Huang C.S., Yue C.T., Wu C.W. and Shen C.Y., Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene 20: 3814-3823, 2001.
17. Guilford P., Hopkins J., Harraway J., McLeod M., McLeod N., Harawira P., Taite H., Secular R., Miller A. and Reeve A.E., E-cadherin germline mutations in familial gastric cancer. Nature 392: 402-405, 1998.
18. Kumar R., Wang R.A., Mazumdar A., Talukder A.H., Mandal M., Yang Z., Bagheri-Yarmand R., Sahin A., Hortobagyi G., Adam L., Barnes C.J. and Vadlamudi R.K., A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature 418: 654-657, 2002.
19. Yang P.S., Yang T.L., Liu C.L., Wu C.W. and Shen C.Y., A case-control study of breast cancer in Taiwan. Br. J. Cancer 75: 752-756, 1997.
20. Lo Y.L., Yu J.C., Huang C.S., Tseng S.L., Chang T.M., Chang K.J., Wu C.W. and Shen C.Y., Allelic loss of the BRCA1 and BRCA2 genes and other regions on 17q and 13q in breast cancer among women from Taiwan (area of low incidence but early onset). Int. J. Cancer 79: 580-587, 1998.
21. Huang C.S., Chern H.D., Chang K.J., Cheng C.W., Hsu S.M. and Shen C.Y., Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res. 59: 4870-4875, 1999.
22. Cheng T.C., Chen S.T., Huang C.S., Fu Y.P., Yu J.C., Cheng C.W., Wu P.E. and Shen C.Y., Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility. Int. J. Cancer 113: 345-353, 2005.
23. Lung J.C., Chu J.S., Yu J.C., Yue C.T., Lo Y.L., Shen C.Y. and Wu C.W., Aberrant expression of cell cycle regulator cyclin D1 in breast cancer is related to chromosomal genomic instability. Gene Chromosome Cancer 34: 276-284, 2002.
24. Fu Y.P., Yu J.C., Cheng T.C., Lou M.A., Hsu G.C., Wu C.Y., Chen S.T., Wu H.S., Wu P.E. and Shen C.Y., Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility. Cancer Res. 63: 2440-2446, 2003.
25. Lo Y.L., Yu J.C., Chen S.T., Yang H.C., Fann C.S., Mau Y.C. and Shen C.Y., Breast cancer risk associated with genotypic polymorphism of the mitosis-regulating gene Aurora-A/STK15/BTAK. Int. J. Cancer 115: 276-283, 2005.
26. Li L.C., Chui R.M., Sasaki M., Nakajima K., Perinchery G., Au H.C., Nojima D., Carroll P. and Dahiya R., A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res. 60: 873-876, 2000.
27. Shin Y., Kim I.J., Kang H.C., Park J.H., Park H.W., Jang S.G., Lee M.R., Jeong S.Y., Chang H.J., Ku J.L. and Park J.G., A functional polymorphism (-347 G- > GA) in the E-cadherin gene is associated with colorectal cancer. Carcinogenesis 25: 2173-2176, 2004.
28. Ohnishi Y., Tanaka T., Ozaki K., Yamada R., Suzuki H. and Nakamura Y., A high-throughput SNP typing system for genome-wide association studies. J. Hum. Genet. 46: 471-477, 2001.
29. Sellers T.A., Genetic Ancestry and Molecular Epidemiology. Cancer Epidemiol. Biomarkers Prev. 13: 499-500, 2004.
30. Kleinbaum D.G., Kupper L.L. and Morgenstern K.H., Epidemiologic Research: Principles and Quantitative Methods. Van Nostrand Reinhold, NY, 1982 .
31. Kleinbaum D.G., Kupper L.L. and Muller K.E., Applied regression analysis and other multivariable methods. PWS-KENT Publishing Company, Boston, 1998 .
32. Vineis P., Individual susceptibility to carcinogens. Oncogene 23: 6477-6483, 2004.
33. Russo J., Tay L.K. and Russo I.H., Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res. Treat. 2: 5-73, 1982.
34. Johnston S.R. and Dowsett M., Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat. Rev. Cancer 3: 821-831, 2003.
35. Smith I.E. and Dowsett M., Aromatase inhibitors in breast cancer. N. Engl. J. Med. 348: 2431-2442, 2003.
36. Kim M.J., Cardiff R.D., Desai N., Banach-Petrosky W.A., Parsons R., Shen M.M. and Abate-Shen C., Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. USA 99: 2884-2889, 2002.
37. Roberts C.W. and Orkin S.H., The SWI/SNF complex-chromatin and cancer. Nat. Rev. Cancer 4: 133-142, 2004.
38. Versteege I., Sevenet N., Lange J., Rousseau-Merck M.F., Ambros P., Handgretinger R., Aurias A. and Delattre O., Truncating mutations of hSNF5/INI 1 in aggressive paediatric cancer. Nature 394: 203-206, 1998.
39. Gunduz E., Gunduz M., Ouchida M., Nagatsuka H., Beder L., Tsujigiwa H., Fukushima K., Nishizaki K., Shimizu K. and Nagai N., Genetic and epigenetic alterations of BRG1 promote oral cancer development. Int. J. Oncol. 26: 201-210, 2005.
40. Medina P.P., Carretero J., Fraga M.F., Esteller M., Sidransky D. and Sanchez-Cespedes M., Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors. Genes Chromosomes Cancer 41: 170-177, 2004.
41. Bau D.T., Fu Y.P., Chen S.T., Cheng T.C., Yu J.C., Wu P.E. and Shen C.Y., Breast cancer risk and the DNA double-strand break end-joining capacity of non-homologous end-joining genes are affected by BRCA1. Cancer Res. 64: 5013-5019, 2004.
42. Hazan R.B., Qiao R., Keren R., Badano I. and Suyama K., Cadherin switch in tumor progression. Ann. NY Acad. Sci. 1014: 155-163, 2004.
43. Hatsell S., Rowlands T., Hiremath M. and Cowin P., Beta-catenin and Tcfs in mammary development and cancer. J. Mammary Gland Biol. Neoplasia 8: 145-158, 2003.
44. Guilford P., E-cadherin downregulation in cancer: fuel on the fire?. Mol. Med. Today 5: 172-177, 1999.
45. Okubo T., Truong T.K., Yu B., Itoh T., Zhao J., Grube B., Zhou D. and Chen S., Down-regulation of promoter 1.3 activity of the human aromatase gene in breast tissue by zinc-finger protein, snail (SnaH). Cancer Res. 61: 1338-1346, 2001.